According to the company, two 600-subject trials will be conducted simultaneously in approximately 180 study centers throughout the US and Canada. Subjects will receive rifaximin or placebo (1:1
Under the terms of the agreement, China Yongxin will have exclusive rights to this brand in Jilin Province, which includes the City of Changchun and has a total
ATL/TV1102 Phase IIa trial was a randomized, double-blind, placebo-controlled clinical trial of ATL/TV1102. The goal of the trial was to obtain preliminary evidence of ATL/TV1102’s effectiveness in reducing
In this receptor pharmacology study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV dihydroergotamine (DHE), but did not activate receptors associated with side effects frequently
The first clinical study evaluated the pharmacokinetics, bioequivalence and safety of needle-free sumatriptan DosePro, compared to a needle-based autoinjector, Imitrex STATdose used in the treatment of migraine. DosePro
The two-year investigation uncovered evidence that money changed hands in return for the falsification of clinical data required for drug licences. The discovery led to the suspension of
Each unit was priced at $0.50 and consisted of one share of the company’s common stock and one warrant to purchase one-half share of common stock. Warrants are
This compound is an internally developed, selective, orally-bioavailable small molecule for the treatment of relapsed and refractory chronic myelogenous leukemia. Mike Grey, CEO of SGX Pharmaceuticals, said: “Filing
The data are from two identical randomized multi-center, double-blind, placebo-controlled crossover trials that evaluated 283 men and women who typically had a history of four to five migraines
Presept is a multi-center, multi-national clinical study sponsored by Epigenomics prospectively evaluating the clinical performance of the company’s proprietary biomarker, Septin 9, for colorectal cancer population wide screening
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.